Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


OpenAI May Slash AI Service Prices Amid Growing Rivalry With Anthropic
US Appeals Court Keeps Trump’s 10% Global Tariff in Effect During Ongoing Legal Battle
Trump Signals Opposition to USMCA Renewal as U.S. Reviews Trade Relations with Canada and Mexico
Coupang Hit With Record $409 Million Fine Over Data Breach Affecting 33 Million Users
SpaceX IPO Set for Explosive Debut as Valuation Tops $2.2 Trillion
Trump Administration Defends Anthropic AI Restrictions in Ongoing Federal Lawsuit
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement
Roku Explores Sale Options as Interest Grows in Streaming and Ad Business
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy
Changchun Targets EV Growth as China’s Auto Industry Consolidation Accelerates
Oil Prices Fall as U.S.-Iran Peace Deal Hopes Ease Supply Concerns
Adobe Beats Q2 2026 Estimates, Raises Full-Year Outlook as AI Revenue Surges Despite Stock Drop
Wizz Air Beats Profit Forecast as Cost Controls Offset Industry Challenges
Oracle Stock Falls Despite Earnings Beat as Company Plans $40 Billion Financing for FY2027
Sigma Healthcare Shares Slide Amid Preliminary Boots Acquisition Talks
Asics Considers Onitsuka Tiger Spinoff as Luxury Sneaker Brand Expands Globally
US Dollar Heads for Weekly Loss as Iran Peace Deal Hopes Boost Risk Appetite 



